Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add ...
It was a positive week for the European Medicines Agency’s human medicines committee (CHMP), which recommended the approval ...
Ipsen’s new sponsored TikTok features the popular “Of course” trend and two social influencers, but with a rare disease twist ...
UCB is shaking up its leadership team “to better align with its commitment to growth and innovation, and to better address ...
We’re in a frothy time,” acknowledges Alexandra Snyder, the head of R&D at Generate:Biomedicines. Generate is one of the ...
Cigna’s health services arm Evernorth said on Thursday that it plans to offer a cheaper copycat of AbbVie’s blockbuster drug ...
Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Health ...
Gilead reported sales of $6.6 billion, a 5% increase year-over-year, prompting Mizhuo analysts to write that the ...
Sage Therapeutics is doubling down on the “blockbuster potential” of its postpartum depression drug Zurzuvae, ...
Flindr Therapeutics has secured €20 million ($21 million) in a Series A raise aimed at advancing its lead program through an ...
AstraZeneca put the spotlight on its near-20% revenue growth during first-quarter earnings, driven in part by its success in ...
As part of its sweeping $1.5 billion cost-cutting measure, Bristol Myers Squibb is culling “about 12” programs from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results